AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22538152 — intervention group
Group type: COMPARATOR
Intervention: 8 mm needle with 60 U insulin diluent
Number of subjects: 56
Study 20016247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate method for collection of stratum corneum samples
Number of subjects: 0
Study 20016247 — intervention group
Group type: COMPARATOR
Intervention: Mechanically removed SC samples
Number of subjects: 0
Study 20016247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate method
Number of subjects: 0
Study 18172627 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 20
Study 18172627 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study 15993115 — intervention group
Group type: EXPERIMENTAL
Intervention: Syncage‐C filled with autologous cancellous bone grafts and CSLP (cage group, n=27)
Number of subjects: 53
Study 15993115 — intervention group
Group type: COMPARATOR
Intervention: Autologous tricortical iliac crest bone graft and CSLP (bone graft group, n=26)
Number of subjects: 53
Study 15993115 — intervention group
Group type: EXPERIMENTAL
Intervention: Cage group
Number of subjects: 53
Study 12881395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (OXA) 130 mg/m² over 2 hours
Number of subjects: 54
Study 12881395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with 5-fluorouracil (OXFU) 1000 mg/m²/day, continuous intravenous infusion, days 1-4
Number of subjects: 54
Study 10526733 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning educational program
Number of subjects: 144
Study 10526733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study 8663944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (100 micrograms/d in each nostril)
Number of subjects: 60
Study 8663944 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray (100 micrograms in each nostril every 12 hours)
Number of subjects: 60
Study 1451923 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day astemizole for 3 days
Number of subjects: 6
Study 1451923 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day loratadine for 3 days
Number of subjects: 6
Study 1451923 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day terfenadine forte for 3 days
Number of subjects: 6
Study 6421391 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyadenylic‐polyuridylic acid
Number of subjects: 300
Study 6421391 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 300
Study 29500021 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital information
Number of subjects: 103
Study 29500021 — intervention group
Group type: COMPARATOR
Intervention: Printed information
Number of subjects: 103
Study 26583940 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 30% sucrose (group I, n=45)
Number of subjects: 180
Study 26583940 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking (NNS) (group II, n=45)
Number of subjects: 180
Study 26583940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sucrose and NNS (group III, n=45)
Number of subjects: 180
Study 26583940 — intervention group
Group type: COMPARATOR
Intervention: None (group IV, n=45)
Number of subjects: 180
Study 24412523 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg orally twice a day)
Number of subjects: 60
Study 22509738 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + Er:YAG laser (10 hz, 30 mJ/pulse, 1 min per pocket, apico‐coronal direction in parallel paths with 30 degree angle tips, under water irrigation)
Number of subjects: 27
Study 22509738 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + systemic metronidazole
Number of subjects: 27
Study 22509738 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 27
Study 19841042 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acid intake (mO-3FA)
Number of subjects: 2397
Study 19841042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention for weight loss
Number of subjects: 2397
Study 18045264 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 0
Study 18045264 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 15644067 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg)
Number of subjects: 32
Study 15644067 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (125 mg) + Selegiline (5 mg)
Number of subjects: 32
Study 15644067 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 32
Study 12396241 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate
Number of subjects: 21
Study 12396241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine/stannous fluoride
Number of subjects: 21
Study 12396241 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride
Number of subjects: 21
Study 10540928 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.7 mg/kg body weight)
Number of subjects: 90
Study 10540928 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg body weight)
Number of subjects: 90
Study 7762650 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (1 pmol.kg‐1.min‐1)
Number of subjects: 9
Study 7762650 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-I‐(7‐‐36) amide (0.3 pmol.kg‐1.min‐1)
Number of subjects: 9
Study 7762650 — intervention group
Group type: COMPARATOR
Intervention: CCK-8 (0.5 pmol.kg‐1.min‐1)
Number of subjects: 9
Study 7762650 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl‐1% human serum albumin)
Number of subjects: 9
Study 2324921 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 63
Study 2324921 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 500 mg
Number of subjects: 63
Study 2324921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7002707 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous intestinal contents infusion
Number of subjects: 21
Study 7002707 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 21
Study 7002707 — intervention group
Group type: COMPARATOR
Intervention: Artificial bile acid solution infusion
Number of subjects: 21
Study 7002707 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid concentrations
Number of subjects: 21
Study 30489441 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care breath training program (30-min training followed by 15 min twice daily for 6 weeks)
Number of subjects: 23
Study 30489441 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care breath training program
Number of subjects: 23
Study 25356570 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine plus computer-based cognitive training (CT)
Number of subjects: 34
Study 25356570 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus computer-based cognitive training (CT)
Number of subjects: 34
Study 23117349 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based individually tailored balance, strengthening and walking exercise programme (physiotherapist)
Number of subjects: 40
Study 23117349 — intervention group
Group type: COMPARATOR
Intervention: Home-based education programme (control)
Number of subjects: 40
Study 20689457 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 10
Study 20689457 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (P)
Number of subjects: 10
Study 20689457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinsing 6.4% CHO (R)
Number of subjects: 10
Study 19700798 — intervention group
Group type: EXPERIMENTAL
Intervention: Curd (Indian dahi)
Number of subjects: 80
Study 19700798 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaf protein concentrate (LPC)
Number of subjects: 80
Study 19700798 — intervention group
Group type: COMPARATOR
Intervention: Control (WHO recommended diet for severe malnutrition)
Number of subjects: 80
Study 16676077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (30,000 IU) over four days without concomitant heparin
Number of subjects: 2314
Study 16676077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (30,000 IU) over four days with concomitant heparin
Number of subjects: 2314
Study 16676077 — intervention group
Group type: COMPARATOR
Intervention: Antithrombin (30,000 IU) without concomitant heparin
Number of subjects: 2314
Study 16676077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin plus concomitant heparin
Number of subjects: 2314
Study 16676077 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin with or without concomitant heparin
Number of subjects: 2314
Study 15290119 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐ECD brain SPECT in HT patients
Number of subjects: 16
Study 15290119 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐ECD brain SPECT in NTNG patients
Number of subjects: 16
Study 15290119 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐ECD brain SPECT in healthy controls
Number of subjects: 16
Study 15290119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Asymmetry Index (AI) in HT patients
Number of subjects: 16
Study 11373409 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of vasopressin at 0.04 units/min for 16 hrs
Number of subjects: 16
Study 11373409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as patients receiving catecholamines)
Number of subjects: 16
Study 9413849 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene hollow‐fibre membrane (group 1; 2.2 m2)
Number of subjects: 30
Study 9413849 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene flat‐sheet membrane (group 2; 3.1 m2)
Number of subjects: 30
Study 9413849 — intervention group
Group type: COMPARATOR
Intervention: Silicone envelope membrane (group 3; 3.5 m2)
Number of subjects: 30
Study 9413849 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 9413849 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (Polypropylene hollow‐fibre membrane)
Number of subjects: 30
Study 8481249 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (0.2 mg intravenously)
Number of subjects: 61
Study 8481249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml saline solution)
Number of subjects: 61
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg enoxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg enoxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ciprofloxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin orally
Number of subjects: 341
Study 3325934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g daily for seven days
Number of subjects: 341
Study 3325934 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 341
Study 30568484 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm Training (DT group, n=26)
Number of subjects: 52
Study 30568484 — intervention group
Group type: COMPARATOR
Intervention: Complex Training (Control group, n=21)
Number of subjects: 52
Study 27449926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis (B. infantis)
Number of subjects: 0
Study 27449926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24398898 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with continual visual feedback of frequency error
Number of subjects: 30
Study 24398898 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with elastic bands attached to the lever (resonant system)
Number of subjects: 30
Study 24398898 — intervention group
Group type: COMPARATOR
Intervention: Training without resonance and no feedback
Number of subjects: 30
Study 23139388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 0
Study 23139388 — intervention group
Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 0
Study 20547904 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 additional months of oral valganciclovir (n = 70)
Number of subjects: 136
Study 20547904 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 136
Study 18237364 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 2
Study 18237364 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 2
Study 18237364 — intervention group
Group type: COMPARATOR
Intervention: N-of-1 trials (gabapentin vs placebo)
Number of subjects: 2
Study 18237364 — intervention group
Group type: COMPARATOR
Intervention: N-of-1 trials (celecoxib vs paracetamol)
Number of subjects: 2
Study 16627573 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-only starvation (S)
Number of subjects: 0
Study 16627573 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate/high-fat diet (LC)
Number of subjects: 0
Study 16627573 — intervention group
Group type: COMPARATOR
Intervention: Mixed carbohydrate diet (C)
Number of subjects: 0
Study 14676071 — intervention group
Group type: EXPERIMENTAL
Intervention: alefacept, 7.5 mg, in both courses (cohort 1)
Number of subjects: 553
Study 14676071 — intervention group
Group type: EXPERIMENTAL
Intervention: alefacept, 7.5 mg, in the first course and placebo in the second course (cohort 2)
Number of subjects: 553
Study 14676071 — intervention group
Group type: COMPARATOR
Intervention: placebo in the first course and alefacept, 7.5 mg, in the second course (cohort 3)
Number of subjects: 553
Study 14676071 — intervention group
Group type: EXPERIMENTAL
Intervention: alefacept (both cohorts 1 and 2)
Number of subjects: 553
Study 10721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear opacity (particularly severe nuclear opacity)
Number of subjects: 2520
Study 10721963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed opacities with nuclear
Number of subjects: 2520
Study 8981145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes exposed to spermatozoa for 1 hour (Group A)
Number of subjects: 167
Study 8981145 — intervention group
Group type: COMPARATOR
Intervention: Oocytes exposed to spermatozoa for 16 hours (Group B)
Number of subjects: 167
Study 8981145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes exposed to male factor spermatozoa for 1 hour
Number of subjects: 167
Study 8981145 — intervention group
Group type: COMPARATOR
Intervention: Oocytes exposed to male factor spermatozoa with standard culture interval
Number of subjects: 167
Study 8981145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes exposed to normal spermatozoa for 1 hour
Number of subjects: 167
Study 1479656 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29
Study 1479656 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29
Study 1479656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sheets of nitroglycerin patches (5 mg each)
Number of subjects: 29
Study 1479656 — intervention group
Group type: COMPARATOR
Intervention: 0 sheets of nitroglycerin patches (control group)
Number of subjects: 29
Study 6703268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 6
Study 6703268 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 6
Study 6703268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and Prilocaine (increased dose)
Number of subjects: 6
Study 30191249 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine arm (LBA) - 20 ml 1.3% bupivacaine liposomal mixed with 10 ml 0.5% bupivacaine at the sacrospinous ligament.
Number of subjects: 37
Study 30191249 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine arm (LA) - 30 ml 0.5% lidocaine with 1:200,000 epinephrine local injection at the sacrospinous ligament.
Number of subjects: 37
Study 29665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir-grazoprevir for 12 weeks
Number of subjects: 470
Study 29665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir-grazoprevir for patients with Stage 4 or 5 chronic kidney diseases
Number of subjects: 470
Study 29665097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat with elbasvir-grazoprevir
Number of subjects: 470
Study 26848802 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-10 for 90 days
Number of subjects: 0
Study 25522396 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC)
Number of subjects: 30
Study 25522396 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study 23171588 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical evacuation of the haematoma
Number of subjects: 601
Study 23171588 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative treatment
Number of subjects: 601
Study 19159999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine sustained release (nifedipine SR)
Number of subjects: 93
Study 19159999 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 93
Study 17353373 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD) 0.4 mg/kg administered orally 3 times per day
Number of subjects: 12
Study 17353373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17353373 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPD)
Number of subjects: 12
Study 14732641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and written communication about the risks of the procedure (pamphlet)
Number of subjects: 120
Study 14732641 — intervention group
Group type: COMPARATOR
Intervention: Oral communication about the risks of the procedure (no pamphlet)
Number of subjects: 120
Study 14732641 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and written communication (pamphlet)
Number of subjects: 120
Study 11568067 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 72
Study 11568067 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 72
Study 11568067 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 72
Study 9563071 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir under fed conditions
Number of subjects: 8
Study 9563071 — intervention group
Group type: COMPARATOR
Intervention: Saquinavir under fasted conditions
Number of subjects: 8
Study 7519062 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5 (HES)
Number of subjects: 40
Study 7519062 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin (HA5)
Number of subjects: 40
Study 2742290 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1% eye drops every other night
Number of subjects: 96
Study 2742290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% eye drops every night
Number of subjects: 96
Study 2742290 — intervention group
Group type: COMPARATOR
Intervention: Normal saline eye drops every night
Number of subjects: 96
Study 31381494 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble chicken eggshell membrane (WSEM) 450 mg daily
Number of subjects: 88
Study 31381494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 28915284 — intervention group
Group type: EXPERIMENTAL
Intervention: ET handpiece (small spot size)
Number of subjects: 13
Study 28915284 — intervention group
Group type: EXPERIMENTAL
Intervention: HSS handpiece (large spot size, single pass)
Number of subjects: 13
Study 28915284 — intervention group
Group type: EXPERIMENTAL
Intervention: HSD handpiece (large spot size, double pass)
Number of subjects: 13
Study 26113098 — intervention group
Group type: EXPERIMENTAL
Intervention: CEREC VITABLOCS Mark II
Number of subjects: 60
Study 26113098 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress CAD
Number of subjects: 60
Study 26113098 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max CAD
Number of subjects: 60
Study 23035749 — intervention group
Group type: EXPERIMENTAL
Intervention: six 4‐mg doses of betamethasone every 8 h
Number of subjects: 121
Study 23035749 — intervention group
Group type: COMPARATOR
Intervention: two 12‐mg doses of betamethasone separated by 24 h
Number of subjects: 121
Study 21799914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 1478
Study 21799914 — intervention group
Group type: COMPARATOR
Intervention: Control (no acyclovir)
Number of subjects: 1478
Study 19384914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Electromagnetic Fields (PEMFs)
Number of subjects: 30
Study 19384914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16436398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ads sponsored by Philip Morris or Lorillard
Number of subjects: 832
Study 16436398 — intervention group
Group type: COMPARATOR
Intervention: Ads from the American Legacy Foundation
Number of subjects: 832
Study 16436398 — intervention group
Group type: COMPARATOR
Intervention: Ads about preventing drunk driving
Number of subjects: 832
Study 15652545 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted orthotic
Number of subjects: 11
Study 15652545 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard orthotic
Number of subjects: 11
Study 15652545 — intervention group
Group type: EXPERIMENTAL
Intervention: No orthotic
Number of subjects: 11
Study 15652545 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 11
Study 12002834 — intervention group
Group type: COMPARATOR
Intervention: occlusal splints (group I)
Number of subjects: 72
Study 12002834 — intervention group
Group type: EXPERIMENTAL
Intervention: occlusal splints and supplementary medical therapy (group II)
Number of subjects: 72